Real-World Adoption of the 2021 KDIGO BP Guideline in CKD
Journal of the American Society of Nephrology · 2026-08 · 37 (8) · 1764-1772
DOI: 10.1681/asn.0000001046 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 20.02.2026. Verfasst von Hyeok-Hee Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massa…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Practice Guidelines as Topic, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Grants to Beth Israel Deaconess Medical Center from Abbott, BD, Boston Scientific, Cook, Medtronic, and Philips.
Abstract (Originalsprache)
Key Points The proportion of patients with CKD whose systolic BP was within the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) target increased by only 3.6% after the guideline's publication, remaining at 21.9% in 2024. The mean number of antihypertensive classes among patients with CKD increased minimally, by 0.02 (from 1.53 to 1.55), over the same period. Safety end points were generally comparable between patients with systolic BP above versus within the 2021 KDIGO target. Background The real-world uptake of the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) BP guideline, which lowered the systolic BP target to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
- Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts.
- Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
- Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Baim Institute for Clinical Research, Brookline, Massachusetts.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Hyeok-Hee Lee, So Mi Jemma Cho, Cian P McCarthy, Tae-Hyun Yoo, Rishi K Wadhera, Eric A Secemsky, Pradeep Natarajan
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Grants to Beth Israel Deaconess Medical Center from Abbott, BD, Boston Scientific, Cook, Medtronic, and Philips
Zitieren
APA
Lee, H. H., Cho, S. M. J., McCarthy, C. P., Yoo, T. H., Wadhera, R. K., Secemsky, E. A., & Natarajan, P. (2026). Real-World Adoption of the 2021 KDIGO BP Guideline in CKD. Journal of the American Society of Nephrology, 37(8), 1764-1772. https://doi.org/10.1681/asn.0000001046
Vancouver
Lee HH, Cho SMJ, McCarthy CP, Yoo TH, Wadhera RK, Secemsky EA, et al. Real-World Adoption of the 2021 KDIGO BP Guideline in CKD. Journal of the American Society of Nephrology. 2026;37(8):1764-1772. doi:10.1681/asn.0000001046
BibTeX
@article{Lee2026,
author = {Lee, Hyeok-Hee and Cho, So Mi Jemma and McCarthy, Cian P and Yoo, Tae-Hyun and Wadhera, Rishi K and Secemsky, Eric A and Natarajan, Pradeep},
title = {Real-World Adoption of the 2021 KDIGO BP Guideline in CKD},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {8},
pages = {1764--1772},
doi = {10.1681/asn.0000001046}
}
EUVIMED